“神奇蘑菇”離被批準(zhǔn)用于治療抑郁癥又近了一步

“神奇蘑菇”離被批準(zhǔn)用于治療抑郁癥又近了一步

Looks like Rep. Alexandria Ocasio-Cortez wasn’t tripping when espousing the potential mental health benefits of so-called magic mushrooms. Psilocybin fungi have been deemed worthy of investigation by researchers at King’s College in London who are in the process of determining if and how ‘shrooms could be used as a legitimate treatment for depression.

亞歷山德里亞·奧卡西奧-科爾特斯(Alexandria Ocasio-Cortez)在談到所謂的“神奇蘑菇”對精神健康的潛在益處時，似乎并沒有被絆倒。倫敦國王學(xué)院的研究人員認(rèn)為裸蓋菇素真菌值得研究，他們正在確定“蘑菇”是否以及如何被用于抑郁癥的合法治療。

Their recent study, sponsored by mental-health care firm Compass Pathways, aimed to test “the safety and tolerability profile of psilocybin,” the active ingredient of psychedelic mushrooms, according to company co-founder Dr. Ekaterina Malievskaia.

他們最近的研究由心理保健公司Compass Pathways贊助，據(jù)公司聯(lián)合創(chuàng)始人葉卡捷琳娜·馬里耶夫斯卡婭(Ekaterina Malievskaia)博士說，目的是測試“裸蓋菇素的安全性和耐受性”。裸蓋菇素是迷幻蘑菇的活性成分。

As a result, 89 healthy volunteers were administered 10-milligram and 25-milligram doses of the compound in a double-blind, placebo-controlled trial. To prevent any unplanned trips, the trial was monitored by psychological consultants, according to a statement from researchers.

結(jié)果，89名健康志愿者接受了10毫克和25毫克的雙盲安慰劑對照試驗。根據(jù)研究人員的一份聲明，為了防止任何計劃外的旅行，心理咨詢師對試驗進(jìn)行了監(jiān)控。

And while study participants indeed got high, Bloomberg reports, they also experienced “changes in sensory perception and positive mood alteration.” Even better, the trippindicular truffles had no “negative effects on cognitive and emotional functioning.”

據(jù)彭博社報道，雖然研究參與者確實情緒高漲，但他們也經(jīng)歷了“感官感知的變化和積極情緒的改變”。更妙的是，三叉狀塊菌對“認(rèn)知和情感功能沒有負(fù)面影響”。

The study’s lead investigator, Dr. James Rucker, called the findings “clinically reassuring.” He added that they “support further development of psilocybin as a treatment for patients with mental health problems that haven’t improved with conventional therapy, such as treatment-resistant depression.”

該研究的首席研究員詹姆斯·洛克博士稱這些發(fā)現(xiàn)“在臨床上讓人安心”。他補(bǔ)充說，他們“支持進(jìn)一步開發(fā)裸蓋菇素，將其作為一種治療心理健康問題的藥物，而傳統(tǒng)療法并沒有改善這些問題，比如難治性抑郁癥。”

The next phase of testing psilocybin is already underway with 216 patients in Europe and North America who suffer from depression that hasn’t responded to established medications.

下一階段的裸蓋菇素測試已經(jīng)在歐洲和北美的216名患者中展開，這些患者都患有抑郁癥，對現(xiàn)有的藥物治療沒有反應(yīng)。

It’s unclear when the unorthodox depression treatment will be ready for the psycho-pharmaceutical marketplace. However, the research marks a mental health milestone in a world where ‘shrooms are often associated with Birkenstock-sporting hippies.

目前還不清楚這種非傳統(tǒng)的抑郁癥治療方法何時會進(jìn)入心理藥物市場。然而，這項研究標(biāo)志著心理健康的一個里程碑。